HUP0303372A2 - Vakcina - Google Patents

Vakcina

Info

Publication number
HUP0303372A2
HUP0303372A2 HU0303372A HUP0303372A HUP0303372A2 HU P0303372 A2 HUP0303372 A2 HU P0303372A2 HU 0303372 A HU0303372 A HU 0303372A HU P0303372 A HUP0303372 A HU P0303372A HU P0303372 A2 HUP0303372 A2 HU P0303372A2
Authority
HU
Hungary
Prior art keywords
subject
self
vaccine
autoantibodies
immunogens
Prior art date
Application number
HU0303372A
Other languages
English (en)
Inventor
Claire Ashman
James Scott Crowe
Jonathan Henry Ellis
Alan Peter Lewis
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HUP0303372A2 publication Critical patent/HUP0303372A2/hu
Publication of HUP0303372A3 publication Critical patent/HUP0303372A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgyát saját antigén elleni immunizálásra alkalmas,izolált polipeptid képezi. A találmány tárgyát előnyösen olyan sajátfehérje képezi, amely in vivo beadás esetén autoantitestek képződésétindukálja. A találmány tárgyát előnyösen emberekben az embericitokinek immunogénné alakítása képezi. A találmány tárgyát továbbá azilyen vegyületeket tartalmazó gyógyászati készítmények és ezekalkalmazása gyógyászatban, és ezek előállítására szolgáló eljárásokképezik. Ó
HU0303372A 2001-03-03 2002-03-01 Vaccine HUP0303372A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0105360.2A GB0105360D0 (en) 2001-03-03 2001-03-03 Chimaeric immunogens
PCT/GB2002/000900 WO2002070711A1 (en) 2001-03-03 2002-03-01 Vaccine

Publications (2)

Publication Number Publication Date
HUP0303372A2 true HUP0303372A2 (hu) 2004-01-28
HUP0303372A3 HUP0303372A3 (en) 2008-06-30

Family

ID=9909970

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303372A HUP0303372A3 (en) 2001-03-03 2002-03-01 Vaccine

Country Status (18)

Country Link
US (3) US20050260216A1 (hu)
EP (1) EP1368477A1 (hu)
JP (1) JP4238031B2 (hu)
KR (1) KR20030081490A (hu)
CN (1) CN1543504A (hu)
AU (1) AU2002233560B2 (hu)
BR (1) BR0207819A (hu)
CA (1) CA2439628A1 (hu)
CZ (1) CZ20032373A3 (hu)
GB (1) GB0105360D0 (hu)
HU (1) HUP0303372A3 (hu)
IL (1) IL157498A0 (hu)
MX (1) MXPA03007915A (hu)
NO (1) NO20033882L (hu)
NZ (1) NZ527873A (hu)
PL (1) PL365066A1 (hu)
WO (1) WO2002070711A1 (hu)
ZA (1) ZA200306647B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2245149C2 (ru) * 1999-09-25 2005-01-27 Юниверсити Оф Айова Рисерч Фаундейшн Иммуностимулирующие нуклеиновые кислоты
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
EP1534323A2 (en) * 2002-08-30 2005-06-01 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
AU2003259358A1 (en) * 2002-08-30 2004-03-19 Claire Ashman Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
JP2006504413A (ja) * 2002-09-12 2006-02-09 ファーメクサ エイ／エス 自家グレリンに対する免疫化
CA2514979A1 (en) * 2003-01-31 2004-09-02 Celldex Therapeutics, Inc. Antibody vaccine conjugates and uses therefor
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
JP2007525436A (ja) * 2003-03-24 2007-09-06 マーシア・ファーマ・インコーポレイテッド 炎症症状を処置および予防するための方法および組成物
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
ES2389080T3 (es) * 2004-06-11 2012-10-23 Riken Fármaco que presenta un ligando de células reguladoras contenido en el liposoma
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
LT2484375T (lt) 2006-09-26 2018-07-10 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008131376A2 (en) * 2007-04-23 2008-10-30 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
JP2010527633A (ja) * 2007-05-25 2010-08-19 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｔｏｌｌ様受容体３モジュレーター及びその使用
EA026990B1 (ru) 2007-11-07 2017-06-30 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческой клеткой dec-205
PL2850431T3 (pl) 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN117222664A (zh) * 2021-01-29 2023-12-12 拜耳动物保健有限责任公司 用于破坏自身耐受的疫苗组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
ES2267100T5 (es) * 1994-07-15 2011-04-08 The University Of Iowa Research Foundation Oligonucleótidos inmunomoduladores.
CZ25697A3 (en) * 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
CA2213301C (en) * 1995-02-20 2010-01-26 Amrad Operations Pty. Ltd. Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6518061B1 (en) * 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
EP0759468A1 (en) * 1995-08-10 1997-02-26 Laboratoires Virbac Feline interleukin-4
US5666153A (en) * 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
EP0911401A1 (en) * 1997-10-21 1999-04-28 Bayer Ag Muteins of interleukin 4 showing low-affinity and short-term interaction with the common gamma chain
AU758265B2 (en) * 1998-03-20 2003-03-20 Genzyme Corporation Induction of immunity against tumor self-antigens
US6576232B1 (en) * 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
EP1263785A2 (en) * 1999-11-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated il-13 molecules and their uses

Also Published As

Publication number Publication date
AU2002233560B2 (en) 2006-09-07
WO2002070711A1 (en) 2002-09-12
BR0207819A (pt) 2004-03-02
US20050186209A1 (en) 2005-08-25
ZA200306647B (en) 2004-11-26
JP2005502314A (ja) 2005-01-27
US20030194391A1 (en) 2003-10-16
IL157498A0 (en) 2004-03-28
CA2439628A1 (en) 2002-09-12
MXPA03007915A (es) 2003-12-04
NO20033882L (no) 2003-10-31
CZ20032373A3 (cs) 2004-01-14
PL365066A1 (en) 2004-12-27
CN1543504A (zh) 2004-11-03
JP4238031B2 (ja) 2009-03-11
KR20030081490A (ko) 2003-10-17
GB0105360D0 (en) 2001-04-18
NZ527873A (en) 2005-12-23
EP1368477A1 (en) 2003-12-10
US20050260216A1 (en) 2005-11-24
HUP0303372A3 (en) 2008-06-30
NO20033882D0 (no) 2003-09-02

Similar Documents

Publication Publication Date Title
HUP0303372A2 (hu) Vakcina
HUP0402067A2 (hu) Oltóanyagok
HUP0202885A2 (hu) Oltóanyagok
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
MXPA02005576A (es) Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
PL346299A1 (en) Method of dna vaccination
HUP0300814A2 (hu) Peptidszelekciós módszer
NO980883D0 (no) Forbindelser og fremgangsmåter for immunterapi og diagnose av tuberkulose
HUP0301447A2 (hu) Tiotrópium- és salmeterolsókat tartalmazó kombinációs gyógyszerkészítmények
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
HUP9902327A2 (hu) Humán gp39-elleni humanizált antitestek, az antitesteket tartalmazó készítmények és terápiás alkalmazásuk
IN2012DN00313A (hu)
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
HUP0203972A2 (hu) Antigént és glikolipidet tartalmazó készítmény szublingvális úton történő alkalmazásra
HUP0302874A2 (hu) Eljárás risperidon előállítására
HUP0500238A2 (hu) Interleukin-12 alkalmazása állatgyógyászati vakcina adjuvánsként
HUP0401903A2 (hu) Az ET-743 továbbfejlesztett alkalmazása daganatok kezelésére
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
AU2003271021A1 (en) Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof
HUP9900819A1 (hu) Biciklusos aromás vegyületek, alkalmazásuk a humán- és állatgyógyászatban és a kozmetikában
HUP0300054A1 (hu) Daganatspecifikus állati fehérjék
HUP0402281A2 (hu) Endotelin receptor antagonisták alkalmazása daganatos betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
HUP0204216A2 (en) A new use of antibodies as vaccines
HUP0402071A2 (hu) Csökkentett immunogenitású, módosított leptin
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees